|
 The study updates an earlier one from 2011, in which six volunteers
were successfully treated with various doses of the treatment that
uses a virus to insert genetic material into the liver. The four
additional patients received the highest dose.
"I believe that, scientifically, this is ready for prime time," the
chief author, Dr. Andrew Davidoff of St. Jude Children's Research
Hospital in Memphis, Tennessee, told Reuters Health in a telephone
interview.
The problem, he said, is that the genetically engineered virus that
delivers the cure "is really a bear to make" and better methods to
produce the treatment are desperately needed. To engineer enough
virus to treat the 10 patients required six months of work.
Davidoff and his colleagues found that the higher the dose of the
engineered virus, the more factor IX the body produced. Factor IX is
a protein crucial to blood clotting and is defective in hemophilia B
patients.
The researchers used an adeno-associated virus or AAV, which infects
the liver without causing apparent illness.
The therapy seemed to have no serious side effects and is designed
to eliminate the need to give patients injections of factor IX every
two or three days at a cost of about $250,000 per year.
The treatment produced factor IX levels in a range of 1 percent to 6
percent of normal. But even a few percentage points can be enough to
prevent dangerous bleeding. A single infusion was sufficient.
For the six high-dose recipients, the factor IX level averaged 5.1
percent, "which resulted in a reduction of more than 90 percent in
both bleeding episodes and the use of prophylactic factor IX
concentrate," the research team wrote.
"I think it's going to have a big impact. The study showed both
safety and efficacy and the side effects were minimal," said Dr.
Timothy Nichols, who heads the Francis Owen Blood Research
Laboratory at the University of North Carolina and was not involved
in the study.
[to top of second column] |
"This is a single shot of medicine given to patients who are
treating themselves two or three times a week," he told Reuters
Health by phone. "Suddenly, they don't have to take the medicine
anymore."
Worldwide, about 1 in 25,000 men are born with hemophilia B each
year. It is less common than hemophilia A, which is caused by a
problem with a different protein and affects about 1 in 5,000 men.
Because the genetic code for the clotting factors is carried on the
X chromosome, and males don't have a backup copy of that chromosome
as women do, the condition is almost exclusively a disease of men.
Nichols said most people with hemophilia would be "very eager to
consider the treatment and move forward if production issues can be
resolved."
"Hopefully (the new results) will be a catalyst for us and others to
find a more effective way to produce AAV," Davidoff said. "In fact,
we're in discussions with other companies in terms of investing in
our research for improving production."
SOURCE: http://bit.ly/1t6duWb
New England Journal of Medicine, online November 19, 2014.
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
